



## Alzinova initiates collaboration with PolyPeptide

**Alzinova AB (publ) ("Alzinova" or the "Company") announces today that the Company has signed an agreement with PolyPeptide Laboratories Holding (PolyPeptide) for the production of Alzinova's peptide (A $\beta$ CC).**

As previously announced, Alzinova is preparing for upcoming phase 2 and 3 studies for the vaccine candidate ALZ-101 against Alzheimer's disease. As part of this, the Company has signed an agreement with PolyPeptide for the manufacture of the peptide (A $\beta$ CC) on a large scale for future clinical studies. PolyPeptide is a global market leader in contract development and manufacturing of peptides and peptide-related molecules and is regulatory certified.

The collaboration with PolyPeptide complements an existing development and supply agreement and allows Alzinova to broaden its capacity for forthcoming studies and to strengthen the Company's position in its dialogues with potential partners.

*"The new collaboration with PolyPeptide for development and large-scale manufacturing strengthens the position of Alzinova as an innovative player for the development of the next generation of Alzheimer's drugs. Together we take steps towards improving the lives of millions of people around the world."*, says Kristina Torfgård, CEO of Alzinova.

[MAR]

**For more information, please contact:**

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*

**About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)



*This information is information that Alzinova is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-25 07:50 CEST.*

**Attachments**

**Alzinova initiates collaboration with PolyPeptide**